Vietnam's pathology services are entering a new era of digital transformation as hospitals and laboratories increasingly adopt digital pathology technologies to improve diagnostic accuracy, streamline workflows and expand access to specialist expertise.
While Vietnam-specific market figures are not yet widely published, industry analysis estimates the country's digital pathology market is currently valued at US$15–22 million in 2025 and is projected to reach US$32–45 million by 2030. This rapid growth is being driven by increasing cancer incidence, healthcare digitalisation and growing investment in precision medicine.
The market builds on broader growth within Vietnam's tissue diagnostics sector. According to IMARC Group, the country's tissue diagnostics market was valued at US$23.2 million in 2024 and is forecast to reach US$37.9 million by 2033, with advances in digital pathology and AI-powered diagnostics expected to play a significant role in market expansion.
Globally, digital pathology is also experiencing strong growth. IMARC Group reports that the global digital pathology market reached US$1.11 billion in 2025 and is projected to grow to US$2.35 billion by 2034. Rising demand for faster diagnostics, increasing healthcare digitisation and the integration of artificial intelligence are transforming pathology services worldwide.
Several factors are accelerating adoption across Vietnam:
- Rising incidence of cancer and increasing demand for faster, more accurate pathology diagnoses.
- Growing investment in digital transformation across hospitals and diagnostic laboratories.
- Adoption of whole-slide imaging (WSI), AI-assisted image analysis and cloud-based pathology platforms.
- Expansion of telepathology services, enabling remote consultations and access to specialist expertise.
- Increasing use of digital pathology to support precision medicine, companion diagnostics and multidisciplinary cancer care.
- Integration of digital pathology systems with laboratory information systems (LIS) and hospital information systems to improve workflow efficiency.
Digital pathology is fundamentally changing the way tissue samples are analysed by replacing traditional glass slides with high-resolution digital images that can be viewed, shared and analysed remotely. Artificial intelligence is further enhancing these capabilities by assisting pathologists with tumour detection, biomarker quantification and image interpretation, improving diagnostic consistency while helping address the global shortage of specialist pathologists.
Vietnam is already demonstrating the potential of these technologies. A recent international telepathology collaboration between Ho Chi Minh City Oncology Hospital and the University of Texas Health McGovern Medical School reported a 30% reduction in diagnostic turnaround times, highlighting how digital pathology can improve access to specialist expertise while supporting education and clinical collaboration.
Leading technology providers including Leica Biosystems, Philips Digital Pathology, Roche Diagnostics, Hamamatsu Photonics, 3DHISTECH, Indica Labs, Visiopharm and XIFIN continue to invest in digital pathology platforms that combine high-resolution imaging, cloud connectivity and artificial intelligence to support modern pathology workflows.
As Vietnam continues to modernise its healthcare system and strengthen oncology services, digital pathology is expected to become an essential component of cancer diagnosis, precision medicine and laboratory transformation. For suppliers of pathology imaging systems, AI software, laboratory informatics and diagnostic technologies, Vietnam represents one of Southeast Asia's most promising emerging growth markets.